Author

Bruce E. Sands

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 6.8 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS
TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 6.8 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS

Bruce E. Sands  et al.

FECAL CALPROTECTIN AS A SURROGATE MARKER OF CLINICAL REMISSION, CLINICAL RESPONSE, ENDOSCOPIC IMPROVEMENT, AND HISTO-ENDOSCOPIC MUCOSAL HEALING: UNIFI INDUCTION STUDY
FECAL CALPROTECTIN AS A SURROGATE MARKER OF CLINICAL REMISSION, CLINICAL RESPONSE, ENDOSCOPIC IMPROVEMENT, AND HISTO-ENDOSCOPIC MUCOSAL HEALING: UNIFI INDUCTION STUDY

Bruce E. Sands  et al.

SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION AS AN OPTION FOR MANAGING THE LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE: POST HOC ANALYSIS OF LIBERTY-UC STUDY AND LIBERTY-CD STUDY
SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION AS AN OPTION FOR MANAGING THE LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE: POST HOC ANALYSIS OF LIBERTY-UC STUDY AND LIBERTY-CD STUDY

Bruce E. Sands  et al.

EFFICACY, SAFETY AND IMMUNOGENICITY OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) MONOTHERAPY VERSUS COMBINATION THERAPY WITH IMMUNOSUPPRESSANTS – POST HOC ANALYSIS OF LIBERTY-CD STUDY AND LIBERTY-UC STUDY
EFFICACY, SAFETY AND IMMUNOGENICITY OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) MONOTHERAPY VERSUS COMBINATION THERAPY WITH IMMUNOSUPPRESSANTS – POST HOC ANALYSIS OF LIBERTY-CD STUDY AND LIBERTY-UC STUDY

Bruce E. Sands  et al.

ETRASIMOD IMPROVES QUALITY OF LIFE IN ADULTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 OASIS TRIAL AND OPEN-LABEL EXTENSION
ETRASIMOD IMPROVES QUALITY OF LIFE IN ADULTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 OASIS TRIAL AND OPEN-LABEL EXTENSION

Bruce E. Sands  et al.

ETRASIMOD INDUCTION THERAPY IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A PHASE 2, RANDOMISED, DOUBLE-BLIND SUBSTUDY
ETRASIMOD INDUCTION THERAPY IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A PHASE 2, RANDOMISED, DOUBLE-BLIND SUBSTUDY

Bruce E. Sands  et al.

DISEASE CONTROL AND CHANGES IN INDIVIDUAL TREATMENT OUTCOMES FROM WEEK 14 TO WEEK 52 WITH VEDOLIZUMAB OR ADALIMUMAB IN ULCERATIVE COLITIS: A VARSITY TRIAL POST HOC ANALYSIS
DISEASE CONTROL AND CHANGES IN INDIVIDUAL TREATMENT OUTCOMES FROM WEEK 14 TO WEEK 52 WITH VEDOLIZUMAB OR ADALIMUMAB IN ULCERATIVE COLITIS: A VARSITY TRIAL POST HOC ANALYSIS

Bruce E. Sands  et al.

EARLY AND DURABLE SYMPTOM CONTROL IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH ETRASIMOD (APD334) IN THE RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 OASIS TRIAL AND OPEN LABEL EXTENSION
EARLY AND DURABLE SYMPTOM CONTROL IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH ETRASIMOD (APD334) IN THE RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 OASIS TRIAL AND OPEN LABEL EXTENSION

Bruce E. Sands  et al.

EFFICACY AND SAFETY OF GUSELKUMAB FOR CROHN’S DISEASE THROUGH 3 YEARS: GALAXI-1 LONG-TERM EXTENSION
EFFICACY AND SAFETY OF GUSELKUMAB FOR CROHN’S DISEASE THROUGH 3 YEARS: GALAXI-1 LONG-TERM EXTENSION

Bruce E. Sands  et al.

OBEFAZIMOD IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: EFFICACY AND SAFETY ANALYSIS FROM THE 96-WEEK OPEN-LABEL MAINTENANCE PHASE 2B STUDY
OBEFAZIMOD IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: EFFICACY AND SAFETY ANALYSIS FROM THE 96-WEEK OPEN-LABEL MAINTENANCE PHASE 2B STUDY

Bruce E. Sands  et al.

LONG-TERM UPREGULATION OF MIR-124 IN BLOOD AND RECTAL BIOPSIES OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS RECEIVING OBEFAZIMOD 50 MG DAILY FOR 96-WEEKS
LONG-TERM UPREGULATION OF MIR-124 IN BLOOD AND RECTAL BIOPSIES OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS RECEIVING OBEFAZIMOD 50 MG DAILY FOR 96-WEEKS

Bruce E. Sands  et al.

CORRELATION OF MIR-124 UPREGULATION AND PK PARAMETERS IN BLOOD OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS RECEIVING OBEFAZIMOD FOR 16 WEEKS
CORRELATION OF MIR-124 UPREGULATION AND PK PARAMETERS IN BLOOD OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS RECEIVING OBEFAZIMOD FOR 16 WEEKS

Bruce E. Sands  et al.

EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN'S DISEASE THROUGH 5 YEARS: FINAL RESULTS FROM THE IM-UNITI LONG-TERM EXTENSION
EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN'S DISEASE THROUGH 5 YEARS: FINAL RESULTS FROM THE IM-UNITI LONG-TERM EXTENSION

Bruce E. Sands  et al.

PRA023, AN ANTI-TL1A INHIBITORY ANTIBODY, REDUCED INFLAMMATORY AND FIBROSIS ASSOCIATED BIOMARKERS IN ULCERATIVE COLITIS PATIENTS WHO ACHIEVED CLINICAL REMISSION
PRA023, AN ANTI-TL1A INHIBITORY ANTIBODY, REDUCED INFLAMMATORY AND FIBROSIS ASSOCIATED BIOMARKERS IN ULCERATIVE COLITIS PATIENTS WHO ACHIEVED CLINICAL REMISSION

Bruce E. Sands  et al.

ENDOSCOPIC AND HISTOLOGIC REMISSION AFTER 2 YEARS TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS
ENDOSCOPIC AND HISTOLOGIC REMISSION AFTER 2 YEARS TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS

Bruce E. Sands  et al.

EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-1 STUDY
EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-1 STUDY

Bruce E. Sands  et al.

ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH SIGNIFICANTLY IMPROVED INFLAMMATORY BOWEL DISEASE RELATED QUALITY OF LIFE IN A PHASE 2 TRIAL OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS
ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH SIGNIFICANTLY IMPROVED INFLAMMATORY BOWEL DISEASE RELATED QUALITY OF LIFE IN A PHASE 2 TRIAL OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS

Bruce E. Sands  et al.

CORTICOSTEROID-SPARING EFFECTS OF USTEKINUMAB THERAPY FOR ULCERATIVE COLITIS THROUGH 4 YEARS: UNIFI LONG-TERM EXTENSION
CORTICOSTEROID-SPARING EFFECTS OF USTEKINUMAB THERAPY FOR ULCERATIVE COLITIS THROUGH 4 YEARS: UNIFI LONG-TERM EXTENSION

Bruce E. Sands  et al.

THE EFFICACY OF INDUCTION TREATMENT WITH GUSELKUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 3 QUASAR INDUCTION STUDY RESULTS AT WEEK 12 BY PRIOR ADVANCED THERAPY HISTORY
THE EFFICACY OF INDUCTION TREATMENT WITH GUSELKUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 3 QUASAR INDUCTION STUDY RESULTS AT WEEK 12 BY PRIOR ADVANCED THERAPY HISTORY

Bruce E. Sands  et al.

HEALTH-RELATED QUALITY OF LIFE WITH USTEKINUMAB VERSUS ADALIMUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN BIOLOGIC-NAÏVE PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: PROMIS-29 IN THE SEAVUE STUDY
HEALTH-RELATED QUALITY OF LIFE WITH USTEKINUMAB VERSUS ADALIMUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN BIOLOGIC-NAÏVE PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: PROMIS-29 IN THE SEAVUE STUDY

Bruce E. Sands  et al.

Item 41 - 60 / 73
1 2
3
4